$ #novo nordisk novo nordisk shares overvalued; we’re cautious on insulin/hemophilia competition and glp-1 reliance: novo nordisk released results for 2017 that were slightly disappointing on the top line but relatively in line with our eps… https://t.co/mvesjcrdup https://t.co/ya6pf4kbf8